B of A Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $25
B of A Securities analyst Geoff Meacham initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $25.